Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
Eliem Therapeutics (Nasdaq: ELYM) has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit, scheduled for September 17-18, 2024. The company's management team will be available for one-on-one meetings on Wednesday, September 18, 2024.
Eliem Therapeutics is a biopharmaceutical company focused on developing treatments for autoimmune-driven inflammatory diseases. Their lead candidate, budoprutug, is an anti-CD19 antibody designed to address a range of autoimmune conditions, including:
- Systemic lupus erythematosus
- Lupus nephritis
- Immune thrombocytopenia
- Membranous nephropathy
Investors interested in more information can contact Chris Brinzey at ICR Westwicke.
Eliem Therapeutics (Nasdaq: ELYM) ha annunciato la sua partecipazione al Summit Virtuale sulla Immunologia e Infiammazione 2024 di Stifel, programmato per il 17-18 settembre 2024. Il team di gestione dell'azienda sarà disponibile per incontri one-to-one mercoledì 18 settembre 2024.
Eliem Therapeutics è un'azienda biofarmaceutica focalizzata nello sviluppo di trattamenti per malattie infiammatorie autoimmuni. Il loro candidato principale, budoprutug, è un anticorpo anti-CD19 progettato per affrontare una serie di condizioni autoimmuni, tra cui:
- Lupus eritematoso sistemico
- Nefrite lupica
- Trombocitopenia immune
- Nefropatia membranosa
Gli investitori interessati a maggiori informazioni possono contattare Chris Brinzey di ICR Westwicke.
Eliem Therapeutics (Nasdaq: ELYM) ha anunciado su participación en el Summit Virtual de Inmunología e Inflamación 2024 de Stifel, programado para el 17-18 de septiembre de 2024. El equipo de gestión de la compañía estará disponible para reuniones individuales el miércoles 18 de septiembre de 2024.
Eliem Therapeutics es una compañía biofarmacéutica enfocada en desarrollar tratamientos para enfermedades inflamatorias autoinmunitarias. Su candidato principal, budoprutug, es un anticuerpo anti-CD19 diseñado para abordar una variedad de condiciones autoinmunes, incluyendo:
- Lupus eritematoso sistémico
- Nefritis lúpica
- Trombocitopenia inmune
- Nefropatía membranosa
Los inversores interesados en más información pueden contactar a Chris Brinzey de ICR Westwicke.
Eliem Therapeutics (Nasdaq: ELYM)는 2024년 9월 17-18일에 예정된 Stifel 2024 가상 면역학 및 염증 정상 회담에 참여한다고 발표했습니다. 회사의 경영팀은 2024년 9월 18일 수요일에 1대 1 회의에 참석할 수 있습니다.
Eliem Therapeutics는 자가면역성 염증 질환의 치료제를 개발하는 데 주력하는 생물 의약품 회사입니다. 그들의 주요 후보 budoprutug는 다양한 자가면역 상태를 해결하기 위해 설계된 항 CD19 항체입니다. 포함된 질환은:
- 전신성 홍반성 루푸스
- 루푸스 신염
- 면역성 혈소판 감소증
- 막성 신병증
자세한 정보가 필요한 투자자는 ICR Westwicke의 Chris Brinzey에게 연락할 수 있습니다.
Eliem Therapeutics (Nasdaq: ELYM) a annoncé sa participation au Sommet Virtuel sur l'Immunologie et l'Inflammation 2024 de Stifel, prévu pour le 17-18 septembre 2024. L'équipe de direction de l'entreprise sera disponible pour des réunions individuelles le mercredi 18 septembre 2024.
Eliem Therapeutics est une société biopharmaceutique axée sur le développement de traitements pour les maladies inflammatoires auto-immunes. Leur candidat principal, budoprutug, est un anticorps anti-CD19 conçu pour traiter une variété de conditions auto-immunes, y compris :
- Lupus érythémateux systémique
- Néphrite lupique
- Thrombocytopénie immunitaire
- Néphropathie membranaire
Les investisseurs intéressés par des informations supplémentaires peuvent contacter Chris Brinzey de ICR Westwicke.
Eliem Therapeutics (Nasdaq: ELYM) hat seine Teilnahme am Stifel 2024 Virtuellen Immunologie- und Entzündungsgipfel angekündigt, der für den 17.-18. September 2024 geplant ist. Das Managementteam des Unternehmens wird am Mittwoch, den 18. September 2024, für persönliche Gespräche zur Verfügung stehen.
Eliem Therapeutics ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Behandlungen für autoimmunbedingte entzündliche Erkrankungen spezialisiert hat. Ihr Hauptkandidat, budoprutug, ist ein anti-CD19-Antikörper, der entwickelt wurde, um eine Reihe von Autoimmunerkrankungen anzugehen, darunter:
- Systemischer Lupus erythematodes
- Lupusnephritis
- Immune Thrombozytopenie
- Membranöse Nephropathie
Investoren, die an weiteren Informationen interessiert sind, können Chris Brinzey von ICR Westwicke kontaktieren.
- None.
- None.
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.
Stifel 2024 Virtual Immunology and Inflammation Summit
Date: Wednesday, September 18, 2024
Format: 1x1 meetings
About Eliem Therapeutics, Inc.
Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia and membranous nephropathy. For more information, please visit https://eliemtx.com/.
Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843
FAQ
When is Eliem Therapeutics participating in the Stifel 2024 Virtual Immunology and Inflammation Summit?
What is the format of Eliem Therapeutics' participation in the Stifel 2024 summit?
What is Eliem Therapeutics' main focus in drug development?
What is budoprutug and what conditions does it target?
